Replies to post #144413 on Anavex Life Sciences Corp (AVXL)

[Talon38]

Mapman, The science review of Anavex's Sigma-1R approach to treating a very broad spectrum of CNS diseases has become virtually unsalable:

- Four to five (maybe more) independent scientific research papers including the ones here from the NIH on the role of the Sigma-1R.

- Very successful preclinical research studies conducted at Neurological Departments at prodigious institutions like WSU and McGill university covering AD. PD, MS. RS AGM, TCS, IS and others. As Falconer66 reminds us, not a failure in the bunch.

- A successful P2 in AD by Alfred Health in AUS

Think there is also a very high probability the 2-73 will be one of the "Lead the Force" drugs to be accepted for trials by the ACTC. With our SAB member, Dr.Paul Aisen, being one of three Directors of the ACTC and the positive P2 with analyzed data, can you think of a list of 5 to 7 promising AD drugs in which 2-73 would not be included?